** J.P. Morgan favours Indian pharma stocks with a domestic focus, like Mankind Pharma MNKI.NS and Abbott India ABOT.NS, over generic drugmakers that have a high U.S. exposure
** Companies like Zydus Lifesciences ZYDU.NS (42% U.S. revenue), Lupin LUPN.NS (34%), and Dr Reddy's REDY.NS (32%) face higher risks due to potential U.S. reciprocal tariffs, says J.P. Morgan
** U.S. President Donald Trump's administration plans to impose tariffs on pharmaceuticals, other sectors from April 2
** If pharma goods are exempted or India waives tariffs, it could benefit Indian exporters but a 10%-25% tariff on pharma imports would negatively impact sector - J.P.Morgan
** JPM also prefers hospitals such as Max Healthcare MAXE.NS, Fortis Healthcare FOHE.NS, Apollo Hospitals APLH.NS, and Rainbow Child RAIB.NS
** Pharma .NIPHARM and healthcare indices .NIFHEIN rise ~0.6% on the day
** Stock movements: Abbott India (+2%), Rainbow (+2.7%), Apollo (+0.3%), Mankind (-1.3%), Zydus (+1.7%); Lupin and Dr Reddy's flat
** Pharma index down 7.1% in 2025 so far, underperforming Nifty 50 .NSEI, which is flat
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.